Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: KLH who wrote (2459)	1/15/1999 9:16:00 AM
From: BWAC	Read Replies (1) \| Respond to of 2553

If buys were/appeared to be 10 to 1 over sales it should move up to 4 soon. It will get there oneday I guess. After what I heard on the conference call I'll be content to hold on for a while and not trade in and out. Management sounded as if it was going to be proactive and do something very positive about Diacrin. Which should hasten Genzl's move toward profitability. Now that I'm somewhat content with my GENZL research. Anybody want to start looking at GZMO. Their message board is dead. But it looks to me like it has a lot more long range potential and risk than GENZL. A cancer application would be marketable in more mass. And even a laboratory rat success has moved some of these type stocks. Thoughts?